Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr272 Inhibitors

Olr272 inhibitors represent a class of compounds that specifically target the olfactory receptor 272 (Olr272), a protein that belongs to the extensive family of G-protein-coupled receptors (GPCRs). These receptors are primarily involved in detecting odorants, which are small, volatile molecules that activate the olfactory system, leading to the perception of smell. Olr272 inhibitors function by binding to this receptor, thereby blocking its ability to interact with specific odorants. This binding can occur through competitive inhibition, where the inhibitor competes with odorant molecules for the active site of Olr272, or through allosteric inhibition, where the inhibitor binds to a different site on the receptor, inducing a conformational change that reduces its activity. The specificity of these inhibitors to Olr272 is of particular interest in the study of olfactory signal transduction and the broader mechanisms of sensory perception.

In the realm of chemical research, Olr272 inhibitors are valuable tools for dissecting the complex molecular pathways involved in olfaction. By inhibiting specific olfactory receptors like Olr272, researchers can better understand the roles that individual receptors play in the detection of distinct odorants and how these receptors contribute to the overall coding of olfactory signals. Additionally, studying the binding kinetics and structural interactions between Olr272 inhibitors and the receptor provides insights into the fundamental principles of receptor-ligand interactions within the GPCR family. This, in turn, can lead to the development of more refined models for predicting olfactory receptor behavior and for exploring the broader implications of receptor inhibition on sensory processing. The exploration of Olr272 inhibitors thus serves as a crucial aspect of advancing our knowledge in the fields of molecular biology, chemistry, and sensory neuroscience.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Canertinib

267243-28-7sc-207397
10 mg
$260.00
3
(0)

EGFR inhibitor, potentially disrupts pathways that Olr272 might be involved in, altering its function.

Selumetinib

606143-52-6sc-364613
sc-364613A
sc-364613B
sc-364613C
sc-364613D
5 mg
10 mg
100 mg
500 mg
1 g
$29.00
$82.00
$420.00
$1897.00
$3021.00
5
(1)

MEK inhibitor, affects the MAPK/ERK pathway, possibly influencing Olr272's signaling cascade.

CH5424802

1256580-46-7sc-364461
sc-364461A
5 mg
50 mg
$191.00
$902.00
(0)

ALK inhibitor, might affect signaling pathways that Olr272 is involved in, thereby influencing its activity.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual EGFR and HER2 inhibitor, can affect signaling pathways potentially relevant to Olr272's function.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

RAF inhibitor, can affect multiple signaling pathways, potentially influencing Olr272 function.

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$94.00
$208.00
1
(1)

MET and VEGFR2 inhibitor, might influence angiogenesis and signaling pathways related to Olr272.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Bruton's tyrosine kinase inhibitor, potentially impacts cell signaling pathways relevant to Olr272.

Vandetanib

443913-73-3sc-220364
sc-220364A
5 mg
50 mg
$167.00
$1353.00
(1)

VEGFR, EGFR, and RET inhibitor, can modulate signaling pathways possibly related to Olr272.

BIBF1120

656247-17-5sc-364433
sc-364433A
5 mg
10 mg
$184.00
$321.00
2
(0)

Inhibitor of PDGFR, FGFR, and VEGFR, could affect signaling pathways Olr272 is involved in.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Multi-kinase inhibitor, might impact pathways that Olr272 is involved in, influencing its activity.